Recruiting
PHASE4
INTERVENTIONAL
NCT06191848
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Participants will receive tirzepatide subcutaneously
Name:
Placebo
Type:
DRUG
Description:
Participants will receive placebo subcutaneously
Primary Outcomes
Measure:
Percentage of patients who undergo knee replacement in the target joint
TimeFrame:
within 72 weeks of randomization
Description:
Percentage of patients who undergo knee replacement in the target joint
Trial Information
NCT ID
NCT06191848
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
University of Melbourne
Last Updated
December 15, 2025